Hansa Biopharma AB (publ) (STO:HNSA)

Market Cap	3.18B
Revenue (ttm)	178.61M
Net Income (ttm)	-641.14M
Shares Out	101.76M
EPS (ttm)	-8.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	473,108
Average Volume	789,901
Open	30.86
Previous Close	30.66
Day's Range	30.48 - 31.52
52-Week Range	19.58 - 42.98
Beta	1.56
RSI	38.31
Earnings Date	Oct 30, 2025

About Hansa Biopharma AB

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 135
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: HNSA

Financial Performance

In 2024, Hansa Biopharma AB's revenue was 171.32 million, an increase of 27.76% compared to the previous year's 134.09 million. Losses were -807.24 million, -2.94% less than in 2023.